低剂量氯胺酮对创伤患者吗啡消耗量的评估:一项随机、双盲、安慰剂对照试验的研究方案(KLOE试验)
KLOE是一项单中心、随机、双盲、安慰剂对照试验,纳入在兩個不同身体区域至少有两处创伤病变、且至少两处区域损伤简明损伤定级评分大于1的成人创伤患者,1:1随机接受氯胺酮或安慰剂。干预组给予氯胺酮0.1 mg/kg负荷30分钟,继以0.15 mg/kg/h持续48小时;对照组给予等容量0.9%氯化钠。研究治疗须在ICU入住后12小时内启动,所有患者均接受方案化多模式镇痛。共同主要终点为48小时累积阿片消耗量(以静脉吗啡等效剂量表示,优效性设计)和最初48小时平均疼痛强度(视觉模拟量表,非劣效界值10 mm)。计划样本量140例。
要点
- KLOE试验纳入成人创伤患者,要求两个不同身体区域至少两处创伤病变,且至少两处区域损伤简明损伤定级评分大于1。
- 干预组氯胺酮方案:0.1 mg/kg负荷30分钟,继以0.15 mg/kg/h持续48小时;对照组给予等容量0.9%氯化钠。
- 研究治疗须在ICU入住后12小时内启动,所有患者均接受方案化多模式镇痛。
- 共同主要终点:48小时累积阿片消耗量(静脉吗啡等效剂量,优效性)和最初48小时平均疼痛强度(视觉模拟量表,非劣效界值10 mm)。
- 计划样本量140例;截至投稿时招募和随访已完成,数据清理、盲态数据审核、数据库锁定和最终统计分析正在进行中。
适用人群与场景
- 成人创伤患者,两个不同身体区域至少有两处创伤病变,且至少两处区域损伤的简明损伤定级评分大于1。
- 研究场景为ICU,研究治疗须在ICU入住后12小时内启动。
- 所有患者均接受方案化多模式镇痛。
诊断标准与关键阈值
- 纳入标准:成人创伤患者;两个不同身体区域至少两处创伤病变;至少两处区域损伤的简明损伤定级评分大于1。
- 非劣效界值:最初48小时平均疼痛强度视觉模拟量表评分的非劣效界值为10 mm。
处置流程与药物剂量
- 干预组:氯胺酮0.1 mg/kg负荷30分钟,继以0.15 mg/kg/h持续48小时。
- 对照组:等容量0.9%氯化钠。
- 研究治疗须在ICU入住后12小时内启动。
- 所有患者均接受方案化多模式镇痛。
- 共同主要终点:48小时累积阿片消耗量(以静脉吗啡等效剂量表示,优效性设计);最初48小时平均疼痛强度(视觉模拟量表,非劣效界值10 mm)。
研究设计与关键结果
- 研究设计:单中心、随机、双盲、安慰剂对照试验,1:1随机分配,计划样本量140例。
- 共同主要终点为48小时累积阿片消耗量(优效性设计,以静脉吗啡等效剂量表示)和最初48小时平均疼痛强度(非劣效性设计,视觉模拟量表,非劣效界值10 mm)。
- 截至投稿时,招募和随访已完成,数据清理、盲态数据审核、数据库锁定和最终统计分析正在进行中。
证据类型、等级与局限
- 证据类型:随机、双盲、安慰剂对照试验的研究方案。
- 试验注册:ClinicalTrials.gov NCT04833816,首次提交于2021年4月5日,首次发布于2021年4月6日;EudraCT 2020-004812-81。
- 局限:原文未报告局限性。
对床旁实践的改变
- 原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Severely injured trauma patients frequently experience intense acute pain, are highly exposed to opioids during early intensive care, and remain at risk for opioid-related adverse events and persistent pain. Although multimodal analgesia is recommended, regional analgesia may be limited in patients with multiple injuries, coagulopathy, or limited local expertise. Low-dose intravenous ketamine is an attractive opioid-sparing strategy because of its analgesic properties and favourable safety profile at analgesic doses. However, prospective randomized evidence for ketamine used specifically as an analgesic adjunct in critically ill trauma patients remains scarce.
METHODS: KLOE is a single-centre, randomized, double-blind, placebo-controlled trial with co-primary objectives of superiority for opioid reduction and non-inferiority for analgesic efficacy. Adult trauma patients with at least two traumatic lesions in two different body regions and at least two regional injuries with an Abbreviated Injury Scale score greater than 1 are randomized 1:1 to receive ketamine or placebo. The intervention consists of ketamine 0.1 mg/kg over 30 min followed by 0.15 mg/kg/h for 48 h; the control group receives volume-matched 0.9% sodium chloride. Study treatment must be started within 12 h after ICU admission. All patients receive protocolized multimodal analgesia. The superiority co-primary endpoint is cumulative opioid consumption at 48 h, expressed as intravenous morphine equivalents. The non-inferiority co-primary endpoint is mean pain intensity over the first 48 h assessed by visual analogue scale, with a non-inferiority margin of 10 mm. The planned sample size was 140 patients.
DISCUSSION: This trial will provide prospective randomized evidence on whether early low-dose ketamine infusion can safely reduce opioid exposure in severely injured trauma patients without compromising analgesia. At the time of manuscript submission, recruitment and follow-up have been completed, while data cleaning, blinded data review, database lock, and final statistical analyses are ongoing. Publication of this protocol is intended to ensure transparency of the pre-specified methodology before reporting the main trial results.
TRIAL REGISTRATION: ClinicalTrials.gov NCT04833816. First submitted on 5 April 2021; first posted on 6 April 2021. EudraCT 2020-004812-81.
参考来源
- Duclos G, Resseguier N, Arbelot C, et al. Ketamine Low dOse Evaluation on morphine consumption in traumatic patients: study protocol for a randomized, double-blind, placebo-controlled trial (KLOE-Trial). Scand J Trauma Resusc Emerg Med. 2026. PMID: 42310772. doi:10.1186/s13049-026-01649-7
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。